NAOV icon

NanoVibronix

0.5802 USD
-0.0045
0.77%
At close Dec 20, 4:00 PM EST
After hours
0.5500
-0.0302
5.21%
1 day
-0.77%
5 days
-0.48%
1 month
-4.89%
3 months
-15.91%
6 months
-22.26%
Year to date
-49.55%
1 year
-43.12%
5 years
-98.88%
10 years
-99.36%
 

About: NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients as well as through distributor agreements.

Employees: 12

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

54% more capital invested

Capital invested by funds: $163K [Q2] → $251K (+$88.2K) [Q3]

13% more funds holding

Funds holding: 8 [Q2] → 9 (+1) [Q3]

6.39% more ownership

Funds ownership: 8.39% [Q2] → 14.78% (+6.39%) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for NAOV.

Financial journalist opinion

Neutral
Business Wire
1 week ago
NanoVibronix Secures $12 Million Minimum Purchase Commitment for PainShield with Extension of Distribution Agreement
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has renewed its exclusive distribution agreement with Ultra Pain Products, Inc. (“UPPI”) for the distribution of the Company's PainShield for another five years. Brian Murphy, CEO of NanoVibronix, commented, "We are thrilled to extend our par.
NanoVibronix Secures $12 Million Minimum Purchase Commitment for PainShield with Extension of Distribution Agreement
Neutral
Business Wire
1 month ago
NanoVibronix Provides Business Update
TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today provided an update on recent business developments. Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., commented, “We have made substantial progress over the last several months with regards to expanding distribution, raising commercial awareness a.
NanoVibronix Provides Business Update
Neutral
Business Wire
2 months ago
NanoVibronix Takes Next Step to Partner with Specialist Urology Company to Expand Sales of UroShield in Germany
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (“SAW”) Portable Ultrasonic Therapeutic Devices, today announced it has signed a non-binding term sheet for a license and supply agreement with APOGEPHA Arzneimittel GmbH (“APOGEPHA”), a German pharmaceutical company, which specializes in the development, marketing, sales and distribution of urology product.
NanoVibronix Takes Next Step to Partner with Specialist Urology Company to Expand Sales of UroShield in Germany
Neutral
Business Wire
2 months ago
NanoVibronix Signs Letter of Intent with Potential New Distributor
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed a letter of intent with Medici Medical LTD (“Medici”), a leading distributor of medical products in the Israeli healthcare market, to explore the opportunities for distribution of the Company's UroShield device in Israel. Brian Mur.
NanoVibronix Signs Letter of Intent with Potential New Distributor
Neutral
Business Wire
4 months ago
NanoVibronix Highlights Second Quarter Revenue Growth and Narrowing of Loss from Operations in Letter to Stockholders
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to its stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the second quarter financials and recent business developments. To Our Shareholders: We are committed to our strategic vision of developing, improving and commerciali.
NanoVibronix Highlights Second Quarter Revenue Growth and Narrowing of Loss from Operations in Letter to Stockholders
Neutral
Business Wire
7 months ago
NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the University of Michigan will begin the pilot phase of its clinical trial of UroShield this week. The “pilot” phase of the study is the first component of the broader study. As previously announced on November 28, 2023, the company signed a Research Agree.
NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan
Neutral
Business Wire
7 months ago
NanoVibronix Issues Letter to Stockholders
TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to its stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the first quarter of 2024 and recent business developments. To Our Stockholders: We are committed to our strategic vision of developing, improving and commercializing o.
NanoVibronix Issues Letter to Stockholders
Neutral
Business Wire
7 months ago
NanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield
TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix,” or the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a distribution agreement with CB Medical, LLC (“CB Medical”) for the sale and distribution of the Company's UroShield. UroShield is an ultrasound-based product designed to prevent bacterial colonization a.
NanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield
Neutral
Business Wire
7 months ago
NanoVibronix Announces PainShield Will Be Included in Department of Veteran Affairs' FSS Contract Award
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix,” or the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that effective May 1, 2024, the Company's PainShield product will be included in the U.S. Department of Veteran Affairs' (“VA”) Federal Supply Schedule (“FSS”), a program that supports the healthcare acquisition needs of the VA.
NanoVibronix Announces PainShield Will Be Included in Department of Veteran Affairs' FSS Contract Award
Neutral
Accesswire
7 months ago
NanoVibronix to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024
1x1 Meetings on Thursday, May 2, 2024 ELMSFORD, NY / ACCESSWIRE / April 24, 2024 / NanoVibronix, Inc. (Nasdaq:NAOV) ("NanoVibronix" or the "Company"), a medical device company that produces the UroShieldâ, PainShieldâ and WoundShieldâ Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 9:30 AM (Pacific Time). Brian Murphy, Chief Executive Officer of NanoVibronix, Inc. will be hosting the presentation and answering questions at the conclusion.
NanoVibronix to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024
Charts implemented using Lightweight Charts™